DHT and IGF-1 in peripheral blood lymphocytes: New markers for the biological passport of athletes

A. Mancini, E. Imperlini, A. Alfieri, S. Spaziani, D. Martone, A. Parisi, S. Orrù, P. Buono

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We performed a pilot study using human peripheral blood lymphocytes (PBL) as a novel system to identify new biomarkers of dihydrotestosterone (DHT) and insulin-like growth factor-1 (IGF-1) abuse in sport. First, to obtain a gene signature, we treated cultures of lymphocytes from sedentary males with three doses of 0.237 μg/ml DHT, each of which is 80-fold the physiological concentration in young adult male serum, at days 0, 2 and 4, or with a single dose of 1.25 μg/ml IGF-1, which is 5-fold the physiological concentration in young adult male serum. We then used the Human Genome U133 Plus 2.0 microarray to identify a gene signature related to DHT or IGF-1 administration. Gene expression was evaluated after 7 and 21 days of DHT treatment, and after 24 h, 72 h and 7 days of IGF-1 treatment. Microarray analysis yielded a list of genes whose expression was altered after DHT or IGF-1 treatment. Among these we selected the genes that are most representative of the pathways associated with skeletal and muscular disorders using the IPA bioinformatics tool. We identified six (IDO1, CXCL13, CCL1, GZMB, VDR and IL2RA) and two (FN1 and RAB31) genes that were up-regulated in lymphocytes from sedentary subjects after 7 days of DHT and IGF-1 treatment, respectively. The expression of these genes in lymphocytes from differently trained athletes was either down-regulated or similar to that in lymphocytes from sedentary subjects. This finding suggests that up-regulation was due to the drug and not to physical exercise. In conclusion, we demonstrate that PBL can be useful in anti-doping checks, and we describe new biomarkers of DHT and IGF-1 abuse which can be included in the Athlete's Biological Passport.

Original languageEnglish
Pages (from-to)757-770
Number of pages14
JournalJournal of Biological Regulators and Homeostatic Agents
Volume27
Issue number3
Publication statusPublished - 2013

Fingerprint

Dihydrotestosterone
Somatomedins
Athletes
Biomarkers
Lymphocytes
Gene Expression
Genes
Young Adult
Human Genome
Therapeutics
Microarray Analysis
Computational Biology
Serum
Sports
Up-Regulation
Exercise
Pharmaceutical Preparations

Keywords

  • Biomarkers
  • Doping
  • Gene signature
  • Microarray

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Cancer Research
  • Immunology
  • Physiology (medical)
  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Immunology and Allergy
  • Medicine(all)

Cite this

DHT and IGF-1 in peripheral blood lymphocytes : New markers for the biological passport of athletes. / Mancini, A.; Imperlini, E.; Alfieri, A.; Spaziani, S.; Martone, D.; Parisi, A.; Orrù, S.; Buono, P.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 27, No. 3, 2013, p. 757-770.

Research output: Contribution to journalArticle

@article{8eca98293ea641648a507e0b99f47ae3,
title = "DHT and IGF-1 in peripheral blood lymphocytes: New markers for the biological passport of athletes",
abstract = "We performed a pilot study using human peripheral blood lymphocytes (PBL) as a novel system to identify new biomarkers of dihydrotestosterone (DHT) and insulin-like growth factor-1 (IGF-1) abuse in sport. First, to obtain a gene signature, we treated cultures of lymphocytes from sedentary males with three doses of 0.237 μg/ml DHT, each of which is 80-fold the physiological concentration in young adult male serum, at days 0, 2 and 4, or with a single dose of 1.25 μg/ml IGF-1, which is 5-fold the physiological concentration in young adult male serum. We then used the Human Genome U133 Plus 2.0 microarray to identify a gene signature related to DHT or IGF-1 administration. Gene expression was evaluated after 7 and 21 days of DHT treatment, and after 24 h, 72 h and 7 days of IGF-1 treatment. Microarray analysis yielded a list of genes whose expression was altered after DHT or IGF-1 treatment. Among these we selected the genes that are most representative of the pathways associated with skeletal and muscular disorders using the IPA bioinformatics tool. We identified six (IDO1, CXCL13, CCL1, GZMB, VDR and IL2RA) and two (FN1 and RAB31) genes that were up-regulated in lymphocytes from sedentary subjects after 7 days of DHT and IGF-1 treatment, respectively. The expression of these genes in lymphocytes from differently trained athletes was either down-regulated or similar to that in lymphocytes from sedentary subjects. This finding suggests that up-regulation was due to the drug and not to physical exercise. In conclusion, we demonstrate that PBL can be useful in anti-doping checks, and we describe new biomarkers of DHT and IGF-1 abuse which can be included in the Athlete's Biological Passport.",
keywords = "Biomarkers, Doping, Gene signature, Microarray",
author = "A. Mancini and E. Imperlini and A. Alfieri and S. Spaziani and D. Martone and A. Parisi and S. Orr{\`u} and P. Buono",
year = "2013",
language = "English",
volume = "27",
pages = "757--770",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "3",

}

TY - JOUR

T1 - DHT and IGF-1 in peripheral blood lymphocytes

T2 - New markers for the biological passport of athletes

AU - Mancini, A.

AU - Imperlini, E.

AU - Alfieri, A.

AU - Spaziani, S.

AU - Martone, D.

AU - Parisi, A.

AU - Orrù, S.

AU - Buono, P.

PY - 2013

Y1 - 2013

N2 - We performed a pilot study using human peripheral blood lymphocytes (PBL) as a novel system to identify new biomarkers of dihydrotestosterone (DHT) and insulin-like growth factor-1 (IGF-1) abuse in sport. First, to obtain a gene signature, we treated cultures of lymphocytes from sedentary males with three doses of 0.237 μg/ml DHT, each of which is 80-fold the physiological concentration in young adult male serum, at days 0, 2 and 4, or with a single dose of 1.25 μg/ml IGF-1, which is 5-fold the physiological concentration in young adult male serum. We then used the Human Genome U133 Plus 2.0 microarray to identify a gene signature related to DHT or IGF-1 administration. Gene expression was evaluated after 7 and 21 days of DHT treatment, and after 24 h, 72 h and 7 days of IGF-1 treatment. Microarray analysis yielded a list of genes whose expression was altered after DHT or IGF-1 treatment. Among these we selected the genes that are most representative of the pathways associated with skeletal and muscular disorders using the IPA bioinformatics tool. We identified six (IDO1, CXCL13, CCL1, GZMB, VDR and IL2RA) and two (FN1 and RAB31) genes that were up-regulated in lymphocytes from sedentary subjects after 7 days of DHT and IGF-1 treatment, respectively. The expression of these genes in lymphocytes from differently trained athletes was either down-regulated or similar to that in lymphocytes from sedentary subjects. This finding suggests that up-regulation was due to the drug and not to physical exercise. In conclusion, we demonstrate that PBL can be useful in anti-doping checks, and we describe new biomarkers of DHT and IGF-1 abuse which can be included in the Athlete's Biological Passport.

AB - We performed a pilot study using human peripheral blood lymphocytes (PBL) as a novel system to identify new biomarkers of dihydrotestosterone (DHT) and insulin-like growth factor-1 (IGF-1) abuse in sport. First, to obtain a gene signature, we treated cultures of lymphocytes from sedentary males with three doses of 0.237 μg/ml DHT, each of which is 80-fold the physiological concentration in young adult male serum, at days 0, 2 and 4, or with a single dose of 1.25 μg/ml IGF-1, which is 5-fold the physiological concentration in young adult male serum. We then used the Human Genome U133 Plus 2.0 microarray to identify a gene signature related to DHT or IGF-1 administration. Gene expression was evaluated after 7 and 21 days of DHT treatment, and after 24 h, 72 h and 7 days of IGF-1 treatment. Microarray analysis yielded a list of genes whose expression was altered after DHT or IGF-1 treatment. Among these we selected the genes that are most representative of the pathways associated with skeletal and muscular disorders using the IPA bioinformatics tool. We identified six (IDO1, CXCL13, CCL1, GZMB, VDR and IL2RA) and two (FN1 and RAB31) genes that were up-regulated in lymphocytes from sedentary subjects after 7 days of DHT and IGF-1 treatment, respectively. The expression of these genes in lymphocytes from differently trained athletes was either down-regulated or similar to that in lymphocytes from sedentary subjects. This finding suggests that up-regulation was due to the drug and not to physical exercise. In conclusion, we demonstrate that PBL can be useful in anti-doping checks, and we describe new biomarkers of DHT and IGF-1 abuse which can be included in the Athlete's Biological Passport.

KW - Biomarkers

KW - Doping

KW - Gene signature

KW - Microarray

UR - http://www.scopus.com/inward/record.url?scp=84891617885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891617885&partnerID=8YFLogxK

M3 - Article

C2 - 24152843

AN - SCOPUS:84891617885

VL - 27

SP - 757

EP - 770

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 3

ER -